Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors by unknown
Mini-Review 
Urokinase-Type Plasminogen Activator: 
Proenzyme, Receptor, and Inhibitors 
Francesco Blasi,* Jean-Dominique Vassalli,* and Keld Dan0§ 
*International Institute of Genetics and Biophysics, Consiglio Nazionale delle Richerche, Naples, Italy; *Institute of Histology 
and Embryology, University of Geneva, Switzerland; §  Finsen Laboratory, Rigshospitalet, 2100 Copenhagen, Denmark 
N 
'Ew information has recently become available that 
we believe may be of  value for a more precise focus- 
ing of research on the role of  plasminogen activators 
(PAs) in cellular physiology and pathology. PAs convert the 
abundant extracellular zymogen plasminogen into plasmin, 
an active protease that, directly or indirectly, can promote 
degradation of all components of the extracellular matrix. 
The urokinase-type PA (u-PA) is one of two activators with 
similar catalytic specificities that have been described in 
each mammalian species so far studied. Many cell types syn- 
thesize and secrete u-PA at different stages in their life cycle; 
it has been a consistent finding that the expression of u-PA- 
catalyzed proteolysis is under the control of hormonal-type 
mediators, the nature of which depends on the cell popula- 
tion considered, u-PA is thought to play a  central role in 
regulating extracellular proteolysis in a variety of  normal and 
pathological processes involving tissue destruction and cell 
migration, e.g., organ involution, inflammatory reactions, 
and invasive growth of trophoblasts and cancer cells (for 
reviews, see 8, 18, 44, 47, 49, 50). Recent findings show that 
u-PA is synthesized and released from mammalian cells as 
a proenzyme with little or no activity (pro-u-PA), that cells 
possess a specific binding site for u-PA and pro-u-PA, and 
that they can also synthesize different rapidly acting, high 
affinity  inhibitors of PAs. Thus, activation of  pro-u-PA, u-PA 
receptor occupancy, and PA-inhibitors  may finely regulate 
the location and extent of plasminogen activation. 
The Proenzyme 
The human u-PA gene, located on chromosome 10, is 6.4-kb 
long. It is organized in 11 exons and gives rise to a 2.5-kb- 
long mRNA, which in turn yields a single-chain glycosylated 
polypeptide of '~50,000 D (25, 45, 48, 52, 63, 67). Pig and 
mouse u-PA show strong homologies with the human en- 
zyme; mouse u-PA,  however,  contains no N-glycosylation 
site (7, 37). It is the single-chain form of u-PA that is released 
from a variety of cultured normal and neoplastic cell types 
(20, 29, 39, 55, 59, 64, 70),  and that appears to be the pre- 
dominant extracellular form of u-PA in the intact organism 
(30, 54).  Single-chain pro-u-PA is converted by limited pro- 
teolysis into an active Mr 50,000 enzyme consisting of two 
polypeptide chains held together by one disulfide bond; this 
conversion can be catalyzed by plasmin. Results from several 
laboratories have demonstrated that single-chain u-PA is a 
zymogen that in contrast to the two-chain active enzyme has 
little or no proteolytic activity against the natural substrate 
1.  Abbreviations  used  in  this paper:  PA,  plasminogen activator;  u-PA, 
urokinase-type plasminogen activator. 
plasminogen, does not react with macromolecular antipro- 
teases, lacks amidolytic activity against synthetic plasmino- 
gen activator substrates, and is unable to react with the active 
site titrant diisopropylfluorophosphate (2, 18, 26, 29, 39, 55, 
64, 70). It has recently been reported (33, 60), however, that 
certain purified preparations of single-chain u-PA may also 
have catalytic activity; recombinant single-chain u-PA pro- 
duced in Escherichia coli had a catalytic efficiency superior 
to  that of the  two-chain enzyme,  and  single-chain u-PA 
purified from different mammalian sources had variable and 
low, but detectable, catalytic activity. The basis  for these 
differences in the activity of single-chain u-PA preparations 
is not known. It may be related to differences in the extent 
of glycosylation, in the three-dimensional folding, or in a 
partial degradation of the protein, depending on the cell of 
origin or the procedure of purification. 
The u-PA Receptor 
Several  types  of cells  possess  specific  high  affinity (Kd 
~10  -1° M) plasma membrane binding sites for u-PA (9, 57, 
66). Human peripheral blood monocytes, the monocyte-like 
U937  cell, fibroblasts, and HT1080  fibrosarcoma cells all 
have ~105 such specific receptors per cell. Receptor bind- 
ing does not require u-PA catalytic activity, and single-chain 
u-PA  binds  with about  the  same  affinity as  does  the Mr 
~50,000 two-chain enzyme. The region of u-PA that binds 
to the receptor is located on the 135-residue-long  amino ter- 
minal fragment of the A-chain; this amino terminal fragment 
peptide, which comprises two structural domains, a "growth 
factor" region with homology to EGF and a kringle (43), 
binds to the receptor with the same affinity as does intact 
u-PA.  Recent data show that the binding region is located 
within the second loop of the growth factor domain (4).  In 
contrast, the Mr "~33,000 form of u-PA, a partial degrada- 
tion product of the Mr ~,50,000 enzyme that lacks the amino- 
terminal fragment but maintains catalytic activity, does not 
interact with the receptor. Bound u-PA does not dissociate 
rapidly from the cell surface (tt/2 >5 h), nor is it apprecia- 
bly endocytosed and/or degraded. The bound enzyme main- 
tains its plasminogen activating ability, and binding of both 
one-chain and two-chain u-PA to the u-PA receptor on cul- 
tured human monocytes-macrophages results in the genera- 
tion of plasmin-mediated pericellular proteolysis. Thus the 
presence of a u-PA receptor allows cells to acquire surface- 
bound plasminogen-activating ability. It will be of interest to 
determine whether the receptor-bound one-chain protein it- 
self catalyzes  plasmin  formation,  or  whether  it  is  first 
cleaved to the two-chain enzyme. The receptor-bound single 
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min with high efficiency (16). 
Cultured human monocytes and monocyte-like U937 cells 
do produce u-PA, although at a rather low rate. In contrast, 
many malignant cells produce high levels of u-PA.  Do they 
express a u-PA receptor? Human epidermoid carcinoma-de- 
rived A431 and fibrosarcoma HT1080 cells bind little or no 
~25I-labeled u-PA.  However,  uncovering of u-PA receptors 
can be achieved by dissociation of single-chain pro-u-PA 
from the cell surface by short exposure to low pH conditions 
(6, 58).  These cells, therefore, possess u-PA receptors that 
are very similar to,  and possibly identical with,  those of 
U937 cells, except that they are fully occupied by cellular 
pro-u-PA. Immunochemical and kinetic studies have shown 
that pro-u-PA is first secreted from A431 cells and then binds 
to the plasma membrane (58).  Thus, cells that produce little 
or no u-PA may have free u-PA receptors, while those that 
produce larger amounts of the proenzyme have receptors 
constantly saturated through an autocrine process, and may 
now release excess u-PA into the extracellular milieu. 
PA Inhibitors (PAl) 
Two distinct protease inhibitors specific for PAs have re- 
cently been identified and purified. One of these, PAI type-l, 
is released by endothelial cells and some neoplastic cell lines 
(2, 21, 23, 32, 34, 62, 65); it is also present in thrombocytes 
and blood plasma  (22,  68).  The  other,  PAI  type-2,  first 
purified from placenta extracts (5), is also released by cul- 
tured monocytes-macrophages (12, 31, 51, 56, 64, 69). These 
two inhibitors are proteins of Mr •50,000;  they differ in im- 
munological reactivity and in some physiological character- 
istics, such as activation by denaturing agents (27).  Recent 
protein and c-DNA sequence data (3, 24, 31, 41, 42) have 
shown that both inhibitors belong to the serine protease in- 
hibitor family (serpins, see reference 11), PAl type-1 being 
an Argserpin with arginine at its reactive center (3). A third 
PA inhibitor is the fibroblast-produced protease-nexin that, 
in contrast to the PA-specific inhibitors, also inhibits plas- 
min, thrombin, and other trypsin-like serine proteases (53); 
complexes of protease-nexin with proteases bind to fibro- 
blasts in a manner that is independent of the u-PA receptor, 
and are endocytosed and degraded (35).  These three PA in- 
hibitors react with u-PA, but not with pro-u-PA (2, 20, 64). 
Several cultured cell types produce both pro-u-PA and one 
of the PA inhibitors; the proenzyme and the inhibitors have 
been found to coexist in the extracellular milieu. The reac- 
tion rate of the three inhibitors for u-PA is several orders of 
magnitude higher than that of the major plasma protease in- 
hibitors; it is thus likely that they play an important part in 
controlling u-PA-initiated extracellular proteolysis in vivo. It 
is noteworthy that in endotoxin-treated macrophage cultures 
a PA inhibitor is induced, which inhibits the secreted enzyme 
but does not affect the cell-associated (presumably receptor- 
bound) activity (13). Furthermore, the addition of protease 
nexin or of anti-u-PA antibodies blocks the degradation of 
fibroblast-produced extraceUular matrix by human HT 1080 
cells (10). The role of the u-PA receptor in this reaction is 
certainly one of the first questions that should be posed. 
The endothelial cell inhibitor is proteolytically converted 
to an inactive form by u-PA (38) and it may be speculated 
that, apart from inhibiting PA, this inhibitor, its conversion 
product, or a putative released peptide may have other func- 
tions. Another exciting subject for further study is the regu- 
lation of inhibitor production; hormones and growth factors 
have been found to affect inhibitor levels  in different cell 
types (1,  14,  15,  17,  19, 36, 40). 
Modulation of u-PA Activity on Cell Surfaces 
and in Body Fluids 
To summarize our current understanding of the cell biology 
of  u-PA, it is now established that: (a) the product of  the u-PA 
gene is a single-chain proenzyme with little or no activity, 
which is released as such from at least some cell types; (b) 
released pro-u-PA can be bound to cell surfaces via a high 
affinity binding site; (c) pro-u-PA does not react with PA in- 
hibitors, unlike active two-chain u-PA. 
These data suggest a model, probably oversimplified, in 
which receptor-associated u-PA  is the active form in cell 
migration and tissue destruction. Extracellular pro-u-PA in- 
teracts with its plasma membrane receptor, and, after activa- 
tion,  triggers localized proteolysis. It is possible that the 
binding to the receptor may either render the proenzyme 
more  susceptible to  activation by other  factors (plasmin, 
u-PA itself, or other still unidentified components of the sys- 
tem), or directly induce activity in single-chain u-PA, e.g., 
by an allosteric effect.  Furthermore,  receptor-bound two- 
chain u-PA may be protected from certain inhibitors, in con- 
trast to free two-chain u-PA that is rapidly inactivated by PA 
inhibitors. 
In any event, it is clear that u-PA binding to its plasma 
membrane receptor results in focalization of plasminogen 
activation to the close environment of the cell surface; this 
appears  as an optimal configuration if u-PA  is to partic- 
ipate  in  the  proteolytic  events that  are  required  for cell 
migration. In this respect, and although a discussion of the 
biology  of  the  other  mammalian  plasminogen  activator 
tissue-type PA is beyond the scope of the present review, it 
should be pointed out that tissue-type PA binds to fibrin (28, 
46, 61); this interaction, which increases the enzyme's cata- 
lytic activity, suggests a preferred role for tissue-type PA in 
the maintenance of fluidity of the extracellular milieu. 
Implications and Perspectives 
Conflicting data have been obtained relating production of 
u-PA to malignancy. In light of the most recent information, 
this question should be reinvestigated; studies that include 
determination of two-chain  versus  single-chain  forms  of 
u-PA, of receptor distribution and occupancy, and of PA in- 
hibitors are likely to give a clearer picture of the role of u-PA 
in  tumor biology.  Similarly, the  multiple steps  at which 
u-PA-catalyzed proteolysis can be modulated in response to 
growth factors and hormones can now be dissected at the 
molecular level. Finally, the discovery ofa u-PA receptor and 
of PA-specific inhibitors suggests possible approaches for in- 
terfering with the cascade reactions leading to plasminogen 
activation, and may thus help in designing a therapeutic regi- 
men for the control of extracellular proteolysis. 
The evolving picture of the increasing number of factors 
involved in plasminogen activation is reminiscent of the un- 
raveling of other proteolytic cascades, e.g., the coagulation 
and complement systems. It is likely that additional factors 
will be discovered that will complete our, at present, frag- 
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For example, the activation of pro-u-PA under physiological 
conditions is still  poorly understood.  The possible role of 
u-PA receptors in this process appears an attractive target for 
further studies. 
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